A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS—Individuals (n = 476) with HbA1c (A1C) 7.5–10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma glucose targets of ≤6.0 mmol/l (≤108 mg/dl). Outcomes assessed included A1C, percentage achieving A1C ≤7.0%, risk of hypoglycemia, and body weight. RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C ≤7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was −1.58 (P < 0.001). CONCLUSIONS—Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 diabetes achieves guideline-recommended A1C values in most people with aggressive titration. Insulin detemir compared with NPH insulin achieves this with reduced hypoglycemia and less weight gain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The decrease in A1C from triple therapy was greater at 6 months than that of conventional therapy and the superiority was maintained at 3 years.1061”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1061]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648
Research works printed but not linked: 1
- Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 66:193–201, 2004 · DOI · Paper page
Cited by
Items 201–300 of 627
Baxter, M. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0052-9 · Cited by 35
Basal Plus Basal–Bolus Approach in Type 2 Diabetes
Ampudia‐Blasco, F. J., Rossetti, P., & Ascaso, J. F. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0001 · Cited by 35
New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl, E., & Owen, D. R. (2016) · Diabetes Care · doi:10.2337/dcs15-3011 · Cited by 35
Alam, P., Raka, M. A., Khan, S., Sarker, J., Ahmed, N., Nath, P. D., Hasan, N., Mohib, M. M., Tisha, A., & Sagor, M. A. T. (2018) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2018.09.006 · Cited by 33
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
Mehta, R., Goldenberg, R., Katselnik, D., & Kuritzky, L. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1925148 · Cited by 29
Tabák, Á. G., Anderson, J. E., Aschner, P. J., Liu, M., Saremi, A., Stella, P., Tinahones, F. J., Wysham, C., & Meier, J. J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00735-7 · Cited by 29
Initiating insulin in patients with type 2 diabetes
Lau, A. N. C., Tang, T., Halapy, H., Thorpe, K. E., & Yu, C. H. Y. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110779 · Cited by 32
Management of Diabetes-related Hypoglycemia
Boyle, P. J., & Zrebiec, J. F. (2007) · Southern Medical Journal · doi:10.1097/01.smj.0000242864.17631.a2 · Cited by 33
Rašlová, K. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10397 · Cited by 38
Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy
Rakel, R. E. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0061-2 · Cited by 27
Pharmacologic Treatment of Type 2 Diabetes
Tran, L. T., Zielinski, A., Roach, A., Jende, J. A., Householder, A., Cole, E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S., et al. (2015) · The Annals of Pharmacotherapy · doi:10.1177/1060028015573010 · Cited by 33
Arai, K., Okumura, M., Lee, Y., Katayama, H., Mizutani, K., Lin, Y., Park, S., Sawada, K., Toyoda, M., Hojo, H., et al. (2023) · Communications Chemistry · doi:10.1038/s42004-023-01056-4 · Cited by 27
New Insulins and New Aspects in Insulin Delivery
Woo, V. C. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.04.006 · Cited by 29
Why, when and how to initiate insulin therapy in patients with type 2 diabetes
Tibaldi, J. M., & Rakel, R. E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01309.x · Cited by 29
Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy Trial
Lundby‐Christensen, L., Almdal, T., Boesgaard, T. W., Breum, L., Dunn, E., Gade-Rasmussen, B., Gluud, C. N., Hedetoft, C., Jarloev, A., Jensen, T., et al. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00959.x · Cited by 27
Current Strategies for Evaluating, Monitoring, and Treating Type 2 Diabetes Mellitus
Unger, J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.021 · Cited by 33
Parkner, T., Laursen, T., Vestergaard, E. T., Hartvig, H. B., Smedegaard, J., Lauritzen, T., & Christiansen, J. S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02418.x · Cited by 26
Empowering patients during insulin initiation: a real-world approach.
LaSalle, J. R. (2010) · PubMed · Cited by 26
Haukka, J. K., Hoti, F. J., Erästö, P., Saukkonen, T. T., Mäkimattila, S., & Korhonen, P. A. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3534 · Cited by 28
Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes
Weiss, I. A., Valiquette, G., & Schwarcz, M. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181a7b34c · Cited by 27
Intention to Treat — Initiating Insulin and the 4-T Study
McMahon, G. T., & Dluhy, R. G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078196 · Cited by 27
Laubner, K., Molz, K., Kerner, W., Karges, W., Lang, W., Dapp, A., Schütt, M., Best, F., Seufert, J., & Holl, R. W. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2500 · Cited by 27
Barag, S. (2011) · PubMed · Cited by 29
Lajara, R., Davidson, J. A., NIKKEL, C. C., & Morris, T. L. (2016) · Endocrine Practice · doi:10.4158/ep151182.or · Cited by 25
Diabetes screening, diagnosis, and therapy in pediatric patients with type 2 diabetes.
Rodbard, H. W. (2008) · PubMed · Cited by 32
Fahrbach, J. L., Jacober, S. J., Jiang, H. H., & Martin, S. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200514 · Cited by 24
Edelman, S. V., DAILEY, G. E., Flood, T. M., Kuritzky, L., & Renda, S. (2007) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-1-9 · Cited by 24
Meneghini, L. F., Dornhorst, A., Sreenan, S., & on behalf of the PREDICTIVE Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902840871 · Cited by 23
Self-citationDifferences between long-acting insulins for the treatment of type 2 diabetes
Jensen, M. G., Hansen, M., Brock, B., & Rungby, J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.494831 · Cited by 24
Fonseca, V. A., Davidson, J. A., Home, P., Snyder, J., Jellinger, P. S., Toft, A. D., & Barnett, A. H. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.485087 · Cited by 23
Self-citationValentine, W. J., Goodall, G., Aagren, M., Nielsen, S., Palmer, A. J., & Erny-Albrecht, K. M. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0069-z · Cited by 23
Yenigün, M., & Honka, M. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01973.x · Cited by 24
Mezquita‐Raya, P., Reyes‐García, R., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Martínez, J. J. G., Jódar-Gimeno, E., Escalada, J., Gargallo-Fernández, M., Soto-González, A., et al. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.04.005 · Cited by 29
Tran, K., Banerjee, S., Li, H., Cimon, K., Daneman, D., Simpson, S. H., & Campbell, K. (2007) · Cited by 28
for the DIVE study group, Danne, T., Bluhmki, T., Seufert, J., Kaltheuner, M., Rathmann, W., Beyersmann, J., & Bramlage, P. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0051-0 · Cited by 22
Treating the elderly diabetic patient: special considerations
Barski, L., Kezerle, L., & Shalev, L. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48898 · Cited by 31
Home, P., Baik, S. H., González-Gálvez, G., Malek, R., & Nikolajsen, A. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.985788 · Cited by 24
Self-citationInsulin Therapy in the Elderly Patient With Diabetes
Tanwani, L. K. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.02.006 · Cited by 23
Kapitza, C., Fein, S. H., Heinemann, L., Schleusener, D. S., Levesque, S., & Strange, P. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200107 · Cited by 22
Kilpatrick, E. S., Das, A. K., Ørskov, C., & Berntorp, K. E. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802347209 · Cited by 23
Peng, X., McCrimmon, R. J., Shepherd, L. C., Boss, A., LUBWAMA, R. N., DEX, T. A., SKOLNIK, N., Ji, L., Avogaro, A., & Blonde, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00905-y · Cited by 22
Valentine, W. J., Erny-Albrecht, K. M., Ray, J. A., Roze, S., Cobden, D., & Palmer, A. J. (2007) · Advances in Therapy · doi:10.1007/bf02849895 · Cited by 22
Home, P. D., Bolli, G. B., Mathieu, C., Deerochanawong, C., Landgraf, W., Candelas, C., Pilorget, V., Dain, M., & Riddle, M. C. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12329 · Cited by 25
Self-citationContact frequency determines outcome of basal insulin initiation trials in type 2 diabetes
Swinnen, S. G. H. A., & DeVries, J. H. (2009) · Diabetologia · doi:10.1007/s00125-009-1527-0 · Cited by 21
Palmer, J. L., Goodall, G., Nielsen, S., Kotchie, R. W., Valentine, W. J., Palmer, A. J., & Roze, S. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x297295 · Cited by 23
Hypoglycemia and diabetes: increased need for awareness
Shaefer, C. F., Hinnen, D., & Sadler, C. E. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1163255 · Cited by 22
Yokoyama, H., Araki, S., Yamazaki, K., Kawai, K., Shirabe, S., Oishi, M., Kanatsuka, A., Yagi, N., Kabata, D., Shintani, A., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002727 · Cited by 21
Strategy and Tactics for Designing Analogs: Biochemical Characterization of the Large Molecules
Ahn, J., Kassees, K., Lee, T.-K., Manandhar, B., & Yousif, A. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12413-8 · Cited by 24
Home, P. D., Blonde, L., Kalra, S., Ji, L., Guyot, P., Brulle-Wohlhueter, C., Murray, E. M., Shah, R., Sayre, T., & Shaunik, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14148 · Cited by 22
Self-citationA 74-Year-Old Woman With Diabetes
Abrahamson, M. J. (2007) · JAMA · doi:10.1001/jama.297.2.196 · Cited by 21
Diabetes and weight management
Lau, D. C. W. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60006-x · Cited by 26
Diabetes management: optimizing roles for nurses in insulin initiation
Levich, B. (2011) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s16451 · Cited by 24
Luo, J., & Gellad, W. F. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-1286-3 · Cited by 23
Tobin, G. S., Cavaghan, M. K., Hoogwerf, B. J., & McGill, J. B. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12032 · Cited by 23
Dalal, M. R., Xie, L., Başer, O., & DIGENIO, A. G. (2014) · Endocrine Practice · doi:10.4158/ep14290.or · Cited by 19
Ridderstråle, M., Jensen, M. M., Gjesing, R. P., & NISKANEN, L. K. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.768999 · Cited by 19
Rossetti, P., Ampudia‐Blasco, F. J., & Ascaso, J. F. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12256 · Cited by 20
Biphasic insulin aspart in the treatment of type 2 diabetes mellitus
Cucinotta, D., & Russo, G. T. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903391714 · Cited by 19
Diabetes: glycaemic control in type 2 (drug treatments).
Gorter, K. J., de Laar, F. A. V., Janssen, P. G. H., Houweling, S. T., & Rutten, G. E. H. M. (2012) · Europe PMC (PubMed Central) · Cited by 20
Porcellati, F., Lucidi, P., Rossetti, P., Candeloro, P., Andreoli, A. M., Marzotti, S., Cioli, P., Bolli, G. B., & Fanelli, C. G. (2011) · Diabetes Care · doi:10.2337/dc11-1064 · Cited by 19
Meneghini, L. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01816.x · Cited by 19
Kumar, V., Singh, M., Singh, A. P., Pandey, M. S., Kumar, S., & Kumar, S. (2018) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20183930 · Cited by 19
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
Hughes, E. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2015.12.005 · Cited by 18
Mezquita‐Raya, P., Reyes‐García, R., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Martínez, J. J. G., Jódar-Gimeno, E., Martín, J. E. S., Gargallo-Fernández, M., Soto-González, A., et al. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.11.009 · Cited by 27
Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review.
Giugliano, D., Maiorino, M., Bellastella, G., Chiodini, P., & Esposito, K. (2011) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2011.03.005 · Cited by 20
Swinnen, S. G. H. A., Snoek, F. J., Dain, M., DeVries, J. H., Hoekstra, J. B. L., & Holleman, F. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0044 · Cited by 18
Insulin detemir for the treatment of obese patients with type 2 diabetes
Hollander, P. A. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s26980 · Cited by 19
Insulin detemir: A historical perspective on a modern basal insulin analogue
Meneghini, L., Liebl, A., & Abrahamson, M. J. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60007-1 · Cited by 20
Marre, M., Pinget, M., Gin, H., Thivolet, C. H., Hanaire, H. P., Robert, J., & Fontaine, P. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.06.004 · Cited by 18
Suzuki, K., Mitsuma, Y., Sato, T., 安楽, 匠., & Hatta, M. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2741w · Cited by 17
Lefever, E., Vliebergh, J., & Mathieu, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 17
Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin
Tschritter, O., Schäfer, S., Klett, J., Pfäfflin, A., Häring, H., Hennige, A. M., & Fritsche, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01085.x · Cited by 20
Permsuwan, U., Chaiyakunapruk, N., Dilokthornsakul, P., Thavorn, K., & Saokaew, S. (2016) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0228-3 · Cited by 17
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70010-6 · Cited by 17
Actions of insulin beyond glycemic control: A perspective on insulin detemir
Tibaldi, J. M. (2007) · Advances in Therapy · doi:10.1007/bf02849980 · Cited by 18
Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment
Fonseca, V. A., & Haggar, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.17 · Cited by 16
Guillermin, A.-L., Samyshkin, Y., Wright, D., Nguyen, T., & Villeneuve, J. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.561390 · Cited by 18
Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
Patel, D. K., Triplitt, C. L., & Trujillo, J. M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00907-8 · Cited by 17
Shafie, A. A., & Ng, C. H. (2020) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s244884 · Cited by 17
Sørensen, L. P., Brock, B., Mengel, A., Rungby, J., Møller, N., Nielsen, S., Vølund, A., & Schmitz, O. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03026.x · Cited by 16
Hiperglucemia inducida por glucocorticoides
Saigí, I., & Pérez, A. (2011) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2011.04.004 · Cited by 21
Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes
Moghissi, E. S., & FACE (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20071 · Cited by 17
Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine
Davies, M. J., & Khunti, K. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00844.x · Cited by 19
Self-citationEliasson, B., Ekström, N., Wirta, S. B., Odén, A., Fard, M. P., & Svensson, A. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0068-9 · Cited by 16
Rojas, J. M., Printz, R. L., & Niswender, K. D. (2011) · Nutrition and Diabetes · doi:10.1038/nutd.2011.6 · Cited by 18
Niswender, K. D., Piletič, M., Andersen, H., Hiort, L. C., & Hollander, P. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12218 · Cited by 15
Khunti, K., Srinivasan, B. T., Shutler, S., & Davies, M. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01217.x · Cited by 15
Self-citationKuhlmann, M. K., & Schmidt, A. (2014) · Biosimilars · doi:10.2147/bs.s36043 · Cited by 15
Evaluating Older Patients with Diabetes for Insulin Pump Therapy
Stephens, E. A., & Heffner, J. E. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0024 · Cited by 16
Using albumin to improve the therapeutic properties of diabetes treatments
Åhrén, B., & Burke, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01482.x · Cited by 18
Frias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Diabetes - Damages and Treatments
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/1823 · Cited by 17
Levy, P. (2007) · PubMed · Cited by 18
Cardiovascular effects of basal insulins
Mannucci, E., Giannini, S., & Dicembrini, I. (2015) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s43300 · Cited by 15
Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes
JENDLE, J. H., Ridderstråle, M., Torffvit, O., Ericsson, Å., & Larsen, S. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.644408 · Cited by 14
Overnight CSII as supplement to oral antidiabetic drugs in Type 2 diabetes
Parkner, T., Møller, M. K., Chen, J. W., Laursen, T., Jørgensen, C., Smedegaard, J., Lauritzen, T., & Christiansen, J. S. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00748.x · Cited by 14
Practical guidance to insulin management
Meneghini, L., Artola, S., Caputo, S., Damcı, T., Dzida, G. J., Kaiser, M., Khunti, K., Liebl, A., Ligthelm, R. J., Maran, A., et al. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60008-3 · Cited by 14
An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)
Philis‐Tsimikas, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2181 · Cited by 15
Insulin in Frail, Older People with Type 2 Diabetes—Low Threshold for Therapy
Abdelhafiz, A. H., Bisht, S., Kovacevic, I., Pennells, D., & Sinclair, A. J. (2022) · Diabetology · doi:10.3390/diabetology3020028 · Cited by 14
Metadata
- Authors
- Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group
- Affiliations
- Aarhus University Hospital (DK)
- Leicester Royal Infirmary (GB)
- Out-Patient Clinic, NZOZ Eskulap, Gniewkowo, Poland
- Out-Patient Clinic, Novo Nordisk, Bagsværd, Denmark
- Novo Nordisk (Denmark) (DK)
- Newcastle University (GB)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 29
- Issue
- 6
- Pages
- 1269-1274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2149194615
- Cited by
- 627
- References
- 36
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 31 · 2014: 44 · 2013: 59 · 2012: 55
- FWCI
- 48.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin detemir, NPH insulin, basal insulin, type 2 diabetes, insulin-naive patients, oral glucose-lowering agents, adjunctive therapy, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain
- MeSH terms
- Insulin Detemir, Administration, Oral, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Weight Gain, Body Mass Index, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.